Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
266,941,931
-
Total 13F shares
-
52,253,997
-
Share change
-
+311,469
-
Total reported value
-
$30,149,698
-
Put/Call ratio
-
25%
-
Price per share
-
$0.58
-
Number of holders
-
70
-
Value change
-
+$763,514
-
Number of buys
-
21
-
Number of sells
-
48
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2022
As of 31 Dec 2022,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,253,997 shares.
The largest 10 holders included
Alerce Investment Management, L.P., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, BlackRock Inc., RENAISSANCE TECHNOLOGIES LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, FEDERATED HERMES, INC., and FMR LLC.
This page lists
70
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.